These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23861656)

  • 1. Targeting the vasculature of colorectal carcinoma with a fused protein of (RGD)₃-tTF.
    Huang ZJ; Zhao Y; Luo WY; You J; Li SW; Yi WC; Wang SY; Yan JH; Luo Q
    ScientificWorldJournal; 2013; 2013():637086. PubMed ID: 23861656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Arginine-glycine-aspartic polypeptide mediated truncated tissue factor therapy for colorectal carcinoma].
    Huang ZJ; Luo Q; Yan JH; Wang SY
    Zhonghua Wai Ke Za Zhi; 2010 Apr; 48(8):619-24. PubMed ID: 20646482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature.
    Kessler T; Bieker R; Padró T; Schwöppe C; Persigehl T; Bremer C; Kreuter M; Berdel WE; Mesters RM
    Clin Cancer Res; 2005 Sep; 11(17):6317-24. PubMed ID: 16144936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis.
    Hu P; Yan J; Sharifi J; Bai T; Khawli LA; Epstein AL
    Cancer Res; 2003 Aug; 63(16):5046-53. PubMed ID: 12941833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of fusion proteins for selective occlusion of tumor vessels.
    Kessler T; Schwöppe C; Liersch R; Schliemann C; Hintelmann H; Bieker R; Berdel WE; Mesters RM
    Curr Drug Discov Technol; 2008 Mar; 5(1):1-8. PubMed ID: 18537561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Gene expression and activities analysis of a new fusion protein (RGD) 3/tTF].
    Yan JH; Yang GW; Wang JP; Wu N; Zhuang GH
    Sheng Wu Gong Cheng Xue Bao; 2007 May; 23(3):409-12. PubMed ID: 17577984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Humanized monoclonal antibody TNT-3-mediated truncated tissue factor for the treatment of H22 hepatoma-bearing mice].
    Huang ZJ; Wang R; Liu ZZ; Wang SY; Yan JH; Luo Q
    Zhonghua Zhong Liu Za Zhi; 2012 Apr; 34(4):249-53. PubMed ID: 22781034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.
    Bieker R; Kessler T; Schwöppe C; Padró T; Persigehl T; Bremer C; Dreischalück J; Kolkmeyer A; Heindel W; Mesters RM; Berdel WE
    Blood; 2009 May; 113(20):5019-27. PubMed ID: 19179306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue-factor fusion proteins induce occlusion of tumor vessels.
    Schwöppe C; Kessler T; Persigehl T; Liersch R; Hintelmann H; Dreischalück J; Ring J; Bremer C; Heindel W; Mesters RM; Berdel WE
    Thromb Res; 2010 Apr; 125 Suppl 2():S143-50. PubMed ID: 20433995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pHLIP-mediated targeting of truncated tissue factor to tumor vessels causes vascular occlusion and impairs tumor growth.
    Li S; Tian Y; Zhao Y; Zhang Y; Su S; Wang J; Wu M; Shi Q; Anderson GJ; Thomsen J; Zhao R; Ji T; Wang J; Nie G
    Oncotarget; 2015 Sep; 6(27):23523-32. PubMed ID: 26143637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature.
    Cao L; Du P; Jiang SH; Jin GH; Huang QL; Hua ZC
    Mol Cancer Ther; 2008 Apr; 7(4):851-61. PubMed ID: 18413798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor.
    Brand C; Schliemann C; Ring J; Kessler T; Bäumer S; Angenendt L; Mantke V; Ross R; Hintelmann H; Spieker T; Wardelmann E; Mesters RM; Berdel WE; Schwöppe C
    Oncotarget; 2016 Feb; 7(6):6774-89. PubMed ID: 26735180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD.
    Sancey L; Ardisson V; Riou LM; Ahmadi M; Marti-Batlle D; Boturyn D; Dumy P; Fagret D; Ghezzi C; Vuillez JP
    Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):2037-47. PubMed ID: 17674000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific tissue factor delivery using a tumor-homing peptide for inducing tumor infarction.
    Shi Q; Zhang Y; Liu S; Liu G; Xu J; Zhao X; Anderson GJ; Nie G; Li S
    Biochem Pharmacol; 2018 Oct; 156():501-510. PubMed ID: 30222966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature.
    Cai W; Chen K; Li ZB; Gambhir SS; Chen X
    J Nucl Med; 2007 Nov; 48(11):1862-70. PubMed ID: 17942800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Growth Inhibition via Occlusion of Tumor Vasculature Induced by N-Terminally PEGylated Retargeted Tissue Factor tTF-NGR.
    Brand C; Fröhlich M; Ring J; Schliemann C; Kessler T; Mantke V; König S; Lücke M; Mesters RM; Berdel WE; Schwöppe C
    Mol Pharm; 2015 Oct; 12(10):3749-58. PubMed ID: 26310827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
    Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
    J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does imaging αvβ3 integrin expression with PET detect changes in angiogenesis during bevacizumab therapy?
    Rylova SN; Barnucz E; Fani M; Braun F; Werner M; Lassmann S; Maecke HR; Weber WA
    J Nucl Med; 2014 Nov; 55(11):1878-84. PubMed ID: 25278514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gd-EDDA/HYNIC-RGD as an MR molecular probe imaging integrin alphanubeta3 receptor-expressed tumor-MR molecular imaging of angiogenesis.
    Huo T; Du X; Zhang S; Liu X; Li X
    Eur J Radiol; 2010 Feb; 73(2):420-7. PubMed ID: 19261416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RGD-Targeted Ultrasound Contrast Agent for Longitudinal Assessment of Hep-2 Tumor Angiogenesis In Vivo.
    Hu Q; Wang XY; Kang LK; Wei HM; Xu CM; Wang T; Wen ZH
    PLoS One; 2016; 11(2):e0149075. PubMed ID: 26862757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.